Vyne Therapeutics Begin Period Cash Flow Over Time
| VYNE Stock | USD 3.92 0.36 8.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vyne Therapeutics Performance and Vyne Therapeutics Correlation. Vyne |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth 0.467 | Return On Assets | Return On Equity |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKTX | 3 K | 9 K | 6 K | 1.1 M | 7.7 M | 3.3 M | 68.9 M | 34.1 M | 34.1 M | 6 M | 5.7 M | 14.1 M | 9.4 M | 13.2 M | 15.2 M | 15.5 M |
| SLRX | 33.9 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M | 66.7 M | 22.4 M | 19.3 M | 6.1 M | 3.7 M | 11.1 M | 29.2 M | 12.1 M | 10.9 M | 18.2 M |
| SABS | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 6.3 M | 12.6 M | 12.6 M | 15 M | 17.3 M | 13 M |
| GOVX | 92.6 K | 1.1 M | 1.2 M | 1 M | 2.5 M | 1.1 M | 1.1 M | 454 K | 312.7 K | 259.7 K | 283.3 K | 9.9 M | 11.4 M | 27.6 M | 31.8 M | 33.3 M |
| UNCY | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 15 K | 63 K | 16.6 M | 455 K | 523.2 K | 497.1 K |
| PULM | 96 K | 96 K | 96 K | 96 K | 96 K | 451 K | 18.9 M | 4.2 M | 3.5 M | 2.8 M | 23.6 M | 31.9 M | 55.5 M | 37.3 M | 42.8 M | 45 M |
| CDTX | 1000 | 1000 | 1000 | 1000 | 185 K | 22.8 M | 62.6 M | 85.4 M | 60.8 M | 74.6 M | 60.3 M | 42.9 M | 62.3 M | 32.7 M | 37.6 M | 50.5 M |
| PHIO | 6.9 M | 6.9 M | 503 K | 5.1 M | 11.4 M | 8.5 M | 5.1 M | 13 M | 3.6 M | 14.9 M | 7 M | 14.3 M | 24.1 M | 11.8 M | 13.6 M | 10.7 M |
| KRON | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 10.2 M | 32.6 M | 250 M | 200.3 M | 78 M | 89.7 M | 105 M |
| VCYT | 2.8 M | 2.8 M | 7.6 M | 14 M | 71.2 M | 35 M | 39.1 M | 59.2 M | 34.5 M | 78.6 M | 159.9 M | 350 M | 173.9 M | 155 M | 178.2 M | 99.9 M |
| LGVN | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 4 M | 1.9 M | 816 K | 25.7 M | 10.5 M | 12.1 M | 9.3 M |
| LYRA | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 24.2 M | 10.1 M | 74.9 M | 46.1 M | 33.9 M | 39 M | 35 M |
| REVB | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 4.5 M | 1.3 M | 5.3 M | 4.7 M | 4.5 M |
| ZURA | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 729.2 K | 1.6 M | 1.8 M | 1.3 M |
| ZVSA | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 724.4 K | 174.7 K | 328.6 K | 5.9 M | 6.8 M | 7.1 M |
| RNAZ | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 204.5 K | 828 K | 20.8 M | 5 M | 5.7 M | 5.9 M |
Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Vyne Therapeutics | VYNE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.92
Check out Vyne Therapeutics Performance and Vyne Therapeutics Correlation. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Vyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.